M 131
Alternative Names: M-131Latest Information Update: 23 Jun 2022
At a glance
- Originator FutureGen Biopharmaceutical
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research T-cell leukaemia; T-cell lymphoma
Most Recent Events
- 14 Jun 2022 Early research in Leukaemia in China (Parenteral) (FutureGen Biopharmaceuticals pipeline, June 2022)
- 14 Jun 2022 Early research in T-cell lymphoma in China (Parenteral) (FutureGen Biopharmaceuticals pipeline, June 2022)
- 14 Jun 2022 FutureGen Biopharmaceuticals plans for IND submission for lymphoma in 2023 (FutureGen Biopharmaceuticals pipeline, June 2022)